A decade has elapsed since the Joint Vascular Societies published recommendations on the operative management of abdominal aortic aneurysms (AAA). 1 During this time, much further information regarding the anticipated natural history of unoperated AAA and outcome of conventional open surgical AAA repair has been accumulated. 2 Two carefully performed prospective randomized trials have been published, with findings that challenge many previously held indications for surgical repair. 3, 4 Finally, within the past 10 years endovascular AAA repair has evolved and currently plays a major role in AAA management. 5 Thus it is clear that revised guidelines for AAA management are necessary. Guidelines are meant to assist physicians in clinical decision making and aim to improve effectiveness of care as well as optimize patient outcomes. In contemporary practice, there is growing emphasis on evidence-based management, and guidelines must therefore be based upon the best available data. It is well recognized that the best evidence (Level I) is derived from properly designed and conducted prospective randomized trials. 6 In regard to AAA management, there are few such trials, and therefore many recommendations are by necessity the result of consensus of participating experts. It should be emphasized that guidelines are not meant to be dictates but rather a framework within which clinicians bring their own judgment in considering unique individual patient circumstances and personal values.
RANDOMIZED TRIALS
Level I evidence for the treatment of small AAA has been provided by two randomized prospective clinical trails conducted in the United Kingdom and the United States. 3, 4 Design and results of both trials were remarkably similar. The United Kingdom (UK) Small Aneurysm Trial Brewster et al 1107 and the Aneurysm Detection and Management Study (ADAM), 4 conducted at VA Medical Centers in the US, each examined more than 1000 patients with AAA of 4.0 cm to 5.4 cm in maximal diameter, randomly assigned to early elective open surgical repair or ultrasonographic or computed tomography (CT) surveillance every 3 to 6 months. In the surveillance cohort, operation was recommended if the AAA expanded to ≥5.5 cm, enlarged >1 cm in 1 year, or became symptomatic. The primary endpoint was death, and mortality analyses were done by intention to treat. Mean follow-up was 4.6 years for the UK Small Aneurysm Trial and 4.8 years for the ADAM trial.
Both trials concluded that surveillance of AAA of 4.0 cm to 5.5 cm was safe in compliant patients, and that early surgery did not result in any long-term survival advantage. While operative mortality in the UK trial was higher (5.8%) than had been anticipated, perioperative mortality in the ADAM trial was only 2.7%. Thus, while the UK trial conclusions had been challenged by some because of the relatively high operative mortality, the ADAM trial effectively overcame this concern.
It is important to note, however, that >60% of patients in the surveillance group in both studies eventually underwent surgical repair of their AAA because of expansion or development of symptoms by the end of the study. This eventual need for surgical repair was also dependent on the size of the AAA at the time of randomization. In the ADAM trial, for instance, 81% of patients with AAA of 5.0 cm to 5.4 cm at entry into the study required surgical repair within the 4.9-year follow-up period, 4 Rupture risk for AAA in the surveillance group was low in both trials ( ≥ l % per year). One must be cautious in inferring that this figure accurately indicates the natural history of untreated AAA ≤5.5 cm, since 75% of patients in the UK trial, for example, had AAA <5.0 cm, and more than 60% of those in the surveillance group were operated on within the study period following developments considered to signify an increased chance of rupture. Therefore, to interpret these data as accurately reflecting the natural history of AAA up to 5.5 cm is likely somewhat misleading.
7
In a sequel to their initial report, the UK Small Aneurysm Trial participants have recently described their findings of extended 10-year (1991-2001) follow-up of surviving UK trial patients. 8 By the end of 2001, an additional 12% of the surveillance group had undergone surgical repair, for a total of 74% of patients in this cohort during the 9-year observation of the trial. This emphasizes the fact that for many patients assigned to watchful waiting, the question is often not "if" but rather "when" aneurysm repair will be necessary. 9 In this scenario, patient preferences should be a guiding consideration. These extended trial data revealed worse late survival in the surveillance group; survival curves crossed at about 3 years. At 8 years, the estimated risk of death was 7.2% lower in the early-surgery group than in the surveillance cohort (P = .03). However, rupture of unrepaired AAA caused only a small proportion of deaths (6%), so that other explanations must he sought to explain the small late survival advantage in the early surgery group. The trial participants theorized that this difference may be attributable to a higher rate of smoking cessation and other favorable lifestyle changes in the surgery group. An additional important observation was that death was attributable to ruptured AAA in 5% of men who died but 14% of women who died. The risk of rupture was 4 times as high among women as among men. The trial participants concluded that the threshold of 5.5 cm diameter may be too high for women.
INDIVIDUAL DECISION-MAKING
The goal of elective AAA repair is to prevent rupture and prolong life. To be most effective, it should be performed when the rupture risk is high compared with operative risk, in patients who will live long enough to enjoy the long-term benefit. Thus, decision making involved in selecting patients for AAA repair is influenced primarily by estimates of ( 1 ) aneurysm rupture risk, (2) elective operative mortality risk, ( 3 ) life expectancy, and (4) patient preference. In the absence of truly accurate data regarding many of these variables, decision making is often a complex and uncertain process. It is increasingly recognized that patient preference, after a complete review of options and anticipated results (true informed consent), must be a very important component in this decision-making process.
RUPTURE RISK
Accurate data on rupture risk are likely the least precise of the several variables which need to be assessed in the decision-making process. This is due to the fact that in the past 3 decades few patients have been followed without intervention; hence, the true natural history of untreated AAA remains somewhat poorly defined. 10 It is accepted that AAA diameter is the best predictor of rupture risk. This was established by natural history studies before the era of widespread elective repair as well as several autopsy studies. The variability of estimates of rupture risk for particular AAA diameters cited in the literature reflects differences in other factors besides maximal diameter which may vary considerably from series to series, and illustrates that other factors in addition to absolute size must be taken into account in each individual case.
11-13
It is clear that there is a substantial increase in rupture risk as AAA diameter increases from 5 cm to 6 cm. In the only population-based study available, Nevitt et al 14 reported no rupture during 5-year follow-up for AAAs <5 cm, but a 5% annual rupture risk for AAA >5 cm at initial presentation. In a more recent analysis of these data, Reed et al estimated annual rupture risk (with 95% confidence intervals) to be 0% (0%-5%) for AAA <4 cm, 1% (0%-5%) per year for 4.0-4.9 cm AAAs, 11% (1%-21%) per year for 5.0-5.9 cm AAAs and 26% (7%-46%) per year for 6.0-6.9 cm AAAs.
15 Similar estimates were obtained from the larger UK Small Aneurysm Trial, where the annual rupture rate was calculated as 0.3% for AAAs <4cm diameter, 1.5% for 4.0-4.9 cm AAAs, and 6.5% for 5.0-5.9 cm AAAs. 16 It is possible that these studies underestimate rupture risk since some AAAs underwent elective repair for rapid expan-sion or symptoms and so were censored before rupture could occur, as previously noted. 7 This issue was considered by Scott et al 1 7 in analysis of 166 small AAAs with an annual rupture rare of 0.7% for 3.0-4.4 cm AAAs and 1.7% for 4.5-4.9 cm AAAs. Since some AAAs underwent elective repair, they reported maximum possible rupture rates (actual rupture rate plus elective surgery rate) of 2.1% for 3.0-4.4 cm AAAs and 10.2% for 4.5-5.9 cm AAAs.
Although most patients with larger AAAs undergo elective repair, Jones et a l l 8 reported annual rupture rates of 12% for 5.0-5.9 cm AAAs and 14% for ≥6 cm AAAs in higher-risk or older patients who refused elective repair. Similar striking data relative to rupture risk of large AAA were recently reported by Lederle and colleagues from the ADAM trial data. The 1-year incidence of probable rupture by initial AAA diameter was 9.4% for AAA of 5.5 cm to 5.9 cm, 10.2%for AAA of 6.0 cm to 6.9 cm, and 32.5% for AAA of 7.0 cm or more. 19 Thus, although there is agreement that rupture risk is very low for AAAs <5 cm diameter, and increases substantially by 6-cm diameter, there is considerable variation in estimates of actual rupture risk reported in the literature for any specific AAA diameter (Table I ).
The simple observation that not all AAAs rupture at a specific diameter indicates that other patient-or aneurysmspecific variables also affect rupture risk. In a multivariate analysis, Cronenwett et al 20 observed that increased initial diameter, hypertension, and chronic obstructive pulmonary disease (COPD) were independently predictive of rupture in patients with small AAAs. By comparing patients with ruptured and intact AAAs at autopsy, Sterpetti et al 21 concluded that larger initial AAA size, hypertension, and bronchiectasis were independently associated with AAA rupture. Smoking was identified as a risk factor for rupture in a study of male civil servants in England where the relative risk of death from AAA rupture increased 4.6-fold for cigarette smokers, 2.4-fold for cigar smokers and fully 14.6-fold for smokers of hand-rolled cigarettes.
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Important new information concerning AAA rupture risk has been obtained from the UK Small Aneurysm Trial data. In a cohort of 2257 patients with 4.0-5.5 cm AAAs, the relative risk of rupture was independently increased by female gender (3.0x), larger initial diameter (2.9x per cm), current smoking ( l . 5 x ) , worse COPD (0.6x per L, FEVI), and higher mean arterial pressure (1.02x per mm Hg). 16 In a review of ruptured AAAs from Finland, 24% of women with rupture had AAA <5.5 cm. 23 These results confirm previous observations and suggest that a 5-cm Table I . Estimated annual rupture risk diameter AAA in a woman has an equivalent risk to a 6-cm diameter AAA in a man.
AAA diameter (cm)
Rupture risk (%/y) Not only does a positive family history of AAA increase the prevalence of AAAs in other first-degree relatives (FDRs), but it also appears to increase rupture risk. Darling et al 24 reported that the frequency of ruptured AAAs increased with the number of FDRs who have AAAs; 15% with 2 FDRs, 29% with 3 FDRs, and 36% with 4 FDRs. Verloes et al 25 found that the rupture rate was 32% in patients with familial aneurysms versus 9% in patients with sporadic aneurysms. However, these studies did not consider other potentially confounding factors, such as AAA size, which might have been different in the familial group. In addition to AAA diameter, many surgeons consider the ratio of diameter to the proximal normal aorta potentially important in determining rupture risk. Intuitively, a 4-cm AAA in a patient with a 1.5-cm diameter native aorta would be at greater risk of rupture than a comparable 4 cm AAA in a patient with a native aortic diameter of 2.5-cm. The validity of this concept, however, has not been proven. Ouriel et al 26 suggested that a relative comparison between aortic diameter and the diameter of the third lumbar vertebra may increase the accuracy for predicting rupture risk, by adjusting for differences in body size. The improvement in prediction accuracy appears minimal, however, when compared with absolute AAA diameter.
Clinical opinion also holds that eccentric or saccular aneurysms represent greater rupture risk than more diffuse, cylindrical aneurysms. Using computer modeling, Vorp et al 27 found that wall stress is substantially increased by an asymmetric bulge in AAAs, In fact, the influence of asymmetry was as important as diameter over the clinically relevant range tested, Fillinger et al have extended this concept to calculate wall stress in AAAs using finite element analysis of three-dimensional CT scans. 28 They found significantly higher wall stress in ruptured or symptomatic AAAs as compared with elective AAAs. In fact, the smallest ruptured aneurysm (4.8-cm diameter) had a calculated wall stress equal to that of a 6.3-cm diameter AAA in the elective repair group. This suggests that calculated wall stress may become a valuable predictor of rupture risk as these techniques become more widely available.
Localized outpouchings or "blebs", ranging from 5 mm to 30 mm in size, can be observed on AAAs intraoperatively or on CT scans. These areas of focal wall weakness demonstrate marked thinning of the medial elastin, and have been suggested to increase rupture risk. 29 Faggioli et al 30 found that impending rupture was significantly greater in patients with such "blisters" than those without (71% vs 29%). The effect of intraluminal thrombus on AAA rupture risk is debated, but a recent study by Schurink et al 31 found that thrombus within an aneurysm does not reduce either mean or pulse pressure near the aneurysm wall and thus does not likely affect rupture risk.
Although rapid AAA expansion is presumed to increase rupture risk, it is difficult to separate this effect from the influence of expansion rate on absolute diameter, which alone could increase rupture risk. AAAs in the 4-cm to 6-cm 12,20,32,33 Two studies have reported that expansion rate was greater in ruptured than intact AAAs, but these ruptured AAAs were also larger, 12,34 Even though not proven conclusively, rapid AAA expansion (>1 cm/y) is generally regarded as a risk factor for rupture and is often used as a criterion for elective repair of small AAAs.
Although average AAA expansion rate can be estimated for a large population, it is important to realize that individual AAAs behave in a more erratic fashion. Periods of rapid expansion may be interspersed with periods of slower expansion and are not predictable, Chang et al 35 found that in addition to large initial AAA diameter, rapid expansion is independently associated with advanced age, smoking, severe cardiac disease, and stroke. The influence of smoking has been confirmed by others. 36, 37 In addition to these factors, hypertension and pulse pressure have been identified as independent predictors of more rapid expansion rate.
20,33,34 Finally, increased thrombus content within an AAA and the extent of the aneurysm wall in contact with thrombus appear to be associated with more rapid expansion.
38,39
Although there is no precise formula that incorporates the risk factors described above to calculate exact rupture risk, they can be used to categorize rupture risk as low, average, or high (Table I I ) .
OPERATIVE RISK
As with rupture risk, reported operative mortality of conventional open surgical repair of AAA varies considerably in the literature. Much of this variability is related to the type of study reported, that is, hospital-based versus population-based series. 41 Many referral-based series from individual centers of excellence describe 30-day perioperative mortality of only 1% to 5% following elective open infrarenal AAA repair.
42-44 Such excellent results demonstrate the low mortality rates that can be achieved in selected referral centers by skilled, well-trained, experienced surgeons. However, these data cannot be generalized to larger populations. Thus, it is now well documented that many recent population-based series employing statewide or national databases indicate higher mortality, in the 4% to 8% range even in contemporary practice.
41,45-53 A review of 64 studies on this subject found an average mortality rate of 5.5%.
33 This is consistent with the findings of the UK Small Aneurysm Trial (5.8%), 3 1996 US Medicare data (5.5%), 2 and the largest available database in the report of Heller et al (5.6%). 47 Results of other population-based studies aresimilar.
54-60 Surprisingly, there also appears to have been little improvement in mortality rates for elective or ruptured AAA repair over the past two decades. 33, 47, 49 Although such generalized experience is important, decision making for individual patients requires a more patient-specific approach. Using individualized estimates of operative risk may clearly identity low-and high-risk subsets of patients and allow more accurate predictions and clinical decisions. Several factors need to be considered. In the Canadian Aneurysm Study, the most significant variables were electrocardiographic (KKG) evidence of ischemia, COPD, and elevated creatinine. 61 If none of these risk factors was present, operative mortality was 1.9%, whereas if all three were noted in a specific patient, 30-day mortality was 50% (Table I I I , online only). Using the same database from the Canadian Aneurysm Study, an alternative predictive model of operative mortality after AAA repair, which includes the patients' age, has also been developed. Postoperative mortality ranges from 1% to 46% (Table IV , online only). Patient age has also been shown to be an important predictor in the UK study. 62 In this study, the overall postoperative mortality rate was 5.6%. In their subanalsysis, postoperative mortality risk was significantly associated with older age, higher serum creatinine level, and lower forced expiratory volume in 1 second (FEV 1 ). The predicted postoperative mortality risk ranged from 2.7% in younger patients with normal creatinine levels and good FEV 1 to 7.8% in older patients with elevated creatinine levels and reduced FEV1. The impact of advancing age has also been shown in many other studies.
53,54
Similarly, a meta-analysis by Steyerberg et al 63 identified independent risk factors for perioperative mortality of elective open AAA repair (Table V) . Based on this analysis, Steyerberg et al also developed a clinical prediction model to estimate the operative mortality risk for individual patients using these factors (Table VI, online only). This scoring system takes into account the independent risk factors plus the average overall elective mortality rate from a specific medical center, Using their scoring system, the predicted operative mortality for a 70-year-old man in a medical center with an average operative mortality rare of 5% could range from 2% if no risk factors were present to 55 In the Canadian Aneurysm Study, patients without evidence of coronary artery disease had a 0.8% mortality rate from cardiac disease compared with 6.2% if any stigmata of coronary disease were present.
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Additional patient-specific factors need to be considered in estimating perioperative mortality risk in addition to age and the presence of cardiac, renal, or pulmonary comorbidities. Several studies have now documented increased death rates in female patients, with an odds ratio of approximately 1.5 greater risk. 52, 56, 63, 66 It is also strikingly clear that mortality risk is strongly influenced by surgeon training and both surgeon and hospital volume of AAA repair, 2, 52, 53, [57] [58] [59] 67 For example, analysis of 1996 US Medicare data revealed 30-day operative mortality of 7.9% for lowvolume (3 or fewer/y) surgeons as compared with 4.0% for high-volume (11 or more repairs/y) surgeons. 2 In 1996, 60% of surgeons who performed elective AAA repair were lowvolume surgeons, 2 Similar findings related to specialty training (vascular surgeons versus general surg e o n s ) a n d h o s pi t a l v ol um e h a ve a l s o b e e n observed.
57,59,67 Thus, it is important for a surgeon to know his or her own individual results in assessing risk and making clinical decisions.
Finally, operative mortality risk is influenced by anatomic or pathologic features of an AAA. Such features present technical difficulties and lead to potential complications during graft implantation and hence may impact mortality risk. Extensive atheromatous disease, thrombus formation, or severe mural calcification at sites of proximal or distal anastomosis or clamp application are examples, although actual quantification of the influence of such considerations on the risk of complications or mortality is difficult. Certainly extension of aneurysmal disease to a juxtarenal level, requiring suprarenal clamping for repair, is associated with increased morbidity and mortality due to the more extensive and complex dissection necessary, obligatory renal ischemia time, and increased hemodynamic stresses secondary to more proximal clamping. [68] [69] [70] [71] [72] Similarly, inflammatory abdominal aortic aneurysms, with adhesion of adjacent bowel, left renal vein, and/or ureters often present technical challenges and are associated with increased morbidity and mortality.
73,74 A major venous anomaly may occur in as much as 3% to 5% of AAAs and increases the risk of hemorrhage during open surgical repair.
75-77 Thus, mortality may be somewhat higher, particularly when such anomalies are not recognized preoperatively and hence unanticipated during repair.
Again, utilizing an individualized assessment of risk factors for each specific patient allows categorization of operative mortality risk into low (l%-3%), moderate (3%-7%), and high (at least 5%-10% or greater) categories which may be useful on a practical clinical level in terms of decision making (Table VII) .
LIFE EXPECTANCY
Alter estimating rupture risk and anticipated mortality of repair, decision making must also consider the patient's life expectancy. On a population basis, age is the best predictor of life expectancy, which in the United States is approximately 18 years for a 60-year-old man decreasing to 5 years for an 85-year-old man. 78 Obviously, however, for an individual patient, other factors that influence life expectancy must also be considered. Most important, of course, are comorbid medical conditions present in each patient.
In general, 5-year survival following AAA repair is reduced compared to age-and sex-matched population data, averaging approximately 60% to 65% as compared with 75% to 80% anticipated, [79] [80] [81] [82] [83] [84] Over the past 2 decades, it appears that the survival rate has not improved significantly, perhaps because selecting higher-risk patients has offset improvements in surgical, medical, and anesthetic management.
As with determination of the risks of AAA rupture and perioperative mortality, individual variables play a considerable role in estimating life expectancy. In the late results of the Canadian Aneurysm Trial, 5-year survival ranged from 27% to 85%. 81 Higher 5-year survival rates were associated with younger age, no history of congestive heart failure, no or minimal angina, no EKG evidence of ischemia, old infarction, evidence of left ventricular hypertrophy or strain or arrhythmia, no significant COPD, and creatinine <1.5, In the large series from the Cleveland Clinic, the predictors of late mortality were age >75 years, a previous history of coronary artery disease (especially with congestive heart failure), chronic pulmonary disease, or creatinine >2.0. 44 Data from Emory University are similar.
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PATIENT PREFERENCE
Active patient participation in the decision-making process is of paramount importance. This is particularly true for the option of endoluminal repair. Some patients are not psychologically suited to having an untreated AAA with an ill-defined rupture risk. In addition, young patients with AAA in the 4.0-cm to 5.5-cm range will very likely come to eventual repair at some point of follow-up, as demonstrated by several series of selective surgery in which 60% to 75% of patients under surveillance eventually underwent repair. 3, 4, 20, 86 The need for future surgery is also strongly influenced by the size of the AAA at the time of diagnosis. In the original UK Small Aneurysm Trial, 53% of patients with aneurysm 4.5 cm to 4.9 cm at the time of randomization underwent surgical repair within the mean 4.9 years of follow-up, while 81% of those with AAA 5.0 cm to 5.4 cm in diameter came to surgery before conclusion of the trial. 3 Hence, it may be the patient's preference to proceed with repair at a smaller size threshold if operative risk is low. In this regard, follow-up outcomes surveys in the UK Small Aneurysm Trial documented that patients randomized to early surgery had more positive improvements in current health perceptions and health-related quality of life than those patients in the surveillance group. 87 Because the rupture risk is relatively low for AAA <5.5 cm, it should be emphasized that operative results must be outstanding to support early repair. Finally, close patient follow-up achieved in many trials may not be attainable in "realworld" everyday practice. It has been well demonstrated that not all patients will be compliant with the close surveillance necessary in an effective program of watchful waiting. 88 Hence early surgery may be preferable in such patients.
DECISION ANALYSIS MODELS
Because of the complex interaction among variables that influence AAA management, formal decision-analysis models have been constructed to aid in risk comparisons. Such models demonstrate that for a 70-year-old man with average life expectancy and average elective operative mortality (5%), AAA repair will improve life expectancy if annual rupture risk exceeds 1.5%, 89 which is the estimated rupture risk for 4.5-cm to 5.0-cm AAA in many studies. For younger patients, the "threshold" AAA diameter (and rupture risk) that justifies elective repair is lower, whereas in older patients the threshold diameter for elective repair increases.
In a recent decision analysis study employing data from the UK Trial, Schermerhorn and colleagues concluded that early surgery may be cost effective for selected patients with small AAA, particularly younger patients (<72 years of age) with larger AAAs (≥4.5 cm). They emphasize, however, that because the gains in life expectancy are relatively small, clinical decision making should be strongly guided by patient preferences.
ENDOVASCULAR REPAIR
Endovascular aneurysm repair (EVAR) emerged in the early 1990s as an alternative treatment for AAA, and has quickly gained an important role in current clinical management. 5 Many studies have demonstrated equivalent early safety and efficacy of EVAR as compared with conventional open surgical repair. [91] [92] [93] [94] [95] In addition, many shortterm benefits of EVAR have been documented, including reduced intensive care unit and hospital lengths of stay (LOS), reduced blood loss, fewer major complications, and more rapid recovery.
91-95 Studies with longer follow-up are inconsistent, however; some mid-term reports suggest equivalent outcomes at 3 to 6 years, 96 Clearly perioperative morbidity is reduced with EVAR as compared with open operation, with significantly fewer major adverse events. The absolute reduction in complications depends upon the level of stratification of severity, but there are consistent, clinically relevant, relative reductions in complication rates with EVAR, ranging from 30% to 70%. These reductions are primarily in cardiac, pulmonary, and gastrointestinal organ systems. While some earlier studies have found an increased incidence of renal and vascular complications, more recent trials with more experienced operators, smaller delivery systems, and improved device designs have shown no differences in these areas. In addition, EVAR should substantially reduce the incidence of operation-related erectile dysfunction which occurs following standard open AAA repair in a substantial percentage of patients with normal function prior to surgery.
111
As a consequence of the reduced incidence, as well as severity, of perioperative complications and the less invasive nature of EVAR, recovery time is markedly quicker as compared with conventional open repair.
91,95 Indeed, recovery time from repair is one of the most striking differences between EVAR and open operation for AAA and highlights the sobering review of Williamson et al 112 who observed that up to one third of patients undergoing standard open AAA repair had failed to fully recover at a mean follow-up of 34 months, and 18% of patients stated they would not undergo AAA repair again knowing the recovery process, an outcome that is clearly age-related. Because of the reduced morbidity and quicker recovery associated with EVAR, many authorities believe that this method of treatment is particularly beneficial to older, higher-risk patients who have appropriate anatomy.
113-115
Endoleak. Mid-term results indicate a generally favorable impact of EVAR on the anticipated natural history of AAA, with limitation of AAA expansion in 80% to 90% of patients and prevention of rupture in 95% to 98%. 5, [97] [98] [99] 116 However, patients must understand potential shortcomings of EVAR that represent a tradeoff for the benefits of less invasive therapy.
5,117 These include persistent or newlydeveloping late endoleak rates of approximately 10% to 20%.
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The true clinical significance of endoleak remains poorly defined, however, and this is indeed a complex and controversial topic. [119] [120] [121] [122] [123] Several studies have shown poor correlation between endoleak and outcome, and many authorities believe that the most common variety of endoleak, Type 2 retrograde branch flow, rarely causes adverse clinical consequences. [124] [125] [126] In contrast, there is general consensus that Type 1 and 3 leaks are clearly associated with adverse events such as continued AAA enlargement and ongoing rupture risk.
119,126,127 It is also now recognized that aneurysm expansion and even rupture may occur in the absence of a discernible endoleak, a phenomenon which has been termed "endotension.
128
Secondary interventions. While AAA sac maximal diameter shrinkage was initially received with enthusiasm, longer follow-up has demonstrated that this may be associated with later adverse effects upon the endograft including limb kinkage or occlusion, modular junctional separations, device migration, or related problems.
129-131 Such consequences of late morphologic changes to the AAA have been termed the "paradox of success.
117 Structural deterioration of endoluminal devices appears to increase with time and can also be a source of treatment failure.
98,100 There is some optimism, however, that such problems will be less frequent in the more recently developed second and third generation devices.
132,133
As a consequence of such potentially adverse events following EVAR, it is well recognized that secondary reinterventions are required in as much as 10% of patients per year. 134 The majority of such reinterventions are catheterbased procedures rather than open surgical operations and are generally successful in correcting the problem and maintaining the integrity of the endovascular repair.
98,134,135 Such procedures most often involve stenting for reduced limb flow, coil embolization for endoleaks, or placement of further proximal or distal stent-graft extender components for migration or endoleak. While less invasive and generally successful, the high rate of such secondary interventions contrasts strikingly with conventional open repair in which reintervention rates are less than 2% in the first 5 years. While late reoperation may be required in some patients following open repair, the need for reoperation is generally a late phenomenon and often occurs a decade or more after the initial operative procedure.
136-139 Thus, although the need for catheter-based reintervention does not necessarily indicate failure of EVAR, it is clearly an issue that patients must understand and accept if they elect to undergo endovascular treatment of their AAA. 91,94,98,127 The need for conversion was most often related to poor patient selection, nonflexible largecaliber first-generation devices, and relative operator inexperience. 140 With advancements in all these areas, early conversions are now rare.
5,141,142 Late conversions, however, continue to be required in 1% to 2% of patients per year.
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Late conversions to open repair are most commonly re quired for progressive AAA enlargement, device migration, structural failure of the endograft, infection of the prosthesis, and, of course, late AAA rupture. As compared with standard open operative AAA repair, late conversion carries a somewhat higher morbidity and mortality risk due to the frequent need for suprarenal clamping, more extensive dissection, and other potential technical pitfalls, and it is clearly associated with increased risk and worse outcomes.
109,140-142
